Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITDAEPS (Basic)EPS (Weighted Average and Diluted)Income towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Summit Therapeutics (SMMT) Profit After Tax (2022 - 2025)

Summit Therapeutics (SMMT) has disclosed Profit After Tax for 4 consecutive years, with -$219.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Profit After Tax fell 258.11% year-over-year to -$219.2 million, compared with a TTM value of -$1.1 billion through Dec 2025, down 387.81%, and an annual FY2025 reading of -$1.1 billion, down 387.81% over the prior year.
  • Profit After Tax was -$219.2 million for Q4 2025 at Summit Therapeutics, up from -$231.8 million in the prior quarter.
  • Across five years, Profit After Tax topped out at -$14.7 million in Q2 2023 and bottomed at -$565.7 million in Q2 2025.
  • Average Profit After Tax over 4 years is -$139.4 million, with a median of -$58.3 million recorded in 2024.
  • The sharpest move saw Profit After Tax skyrocketed 91.98% in 2024, then plummeted 836.84% in 2025.
  • Year by year, Profit After Tax stood at -$19.2 million in 2022, then plummeted by 90.17% to -$36.6 million in 2023, then plummeted by 67.37% to -$61.2 million in 2024, then crashed by 258.11% to -$219.2 million in 2025.
  • Business Quant data shows Profit After Tax for SMMT at -$219.2 million in Q4 2025, -$231.8 million in Q3 2025, and -$565.7 million in Q2 2025.